Latest Conference Articles

At the EHA 2026 Congress, researchers presented novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

Johannes Schetelig, MD, MSc, discusses findings on graft-vs-host disease prophylaxis in unrelated donor allogeneic stem cell transplants.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

VIKTORIA-1 shows gedatolisib regimens double PFS and cut hyperglycemia vs alpelisib in PIK3CA-mutant HR+/HER2– breast cancer.

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

James W. Smithy, MD, MHS, discusses the key findings from a phase 2 trial of IO102-IO103 plus nivolumab/relatlimab in advanced melanoma.

Phase 2 study presented at ASCO 2026 shows fedratinib eases symptoms and shrinks spleens in rare MDS/MPN variants, offering a needed evidence-based option.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.

Saad Z. Usmani, MD, MBA, shares guidance on improving tolerability of belantamab mafodotin based on clinical experience and findings from in the DREAMM-9 trial.

These 5 noteworthy abstracts provide a deeper dive into the 2026 ASCO gastrointestinal cancers data.

Saad Z. Usmani, MD, MBA, discusses the significance of the final analysis of the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

Dr Tolaney discusses ASCENT-04 data, showing sacituzumab govitecan plus pembrolizumab improves PFS in 1L mTNBC across all Trop-2, tBRCA, and HER2 subgroups.